Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ec/ff/29/ecff295f-8f4c-e8f2-8d5c-0c8a88cb945e/mza_11191508321578000071.jpg/600x600bb.jpg

Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

67 episodes

1 month ago

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

All content for Blood Cancer Talks is the property of Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Education

Health & Fitness,

Medicine

Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson

Blood Cancer Talks

43 minutes

2 months ago

Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).

Key Clinical Trials Discussed

1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL

2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL

3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)

4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL

5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL

6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL

7. Additional Studies Mentioned:

R-Pola-Glo Frail Study

DLBCL Classification